Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade
Authors:
- 15 November 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (22) , 6486-6496
Abstract
Biomarkers such as programmed death receptor 1 ligand (PD-L1) expression, tumor mutational burden (TMB), and high microsatellite instability are potentially applicable to predict the efficacy of immune checkpoint blockade (ICB). However, several challenges such as defining the cut-off value, test platform uniformity, and low frequencies limit their broad clinical application. Here we identify comutations in the DNA damage response (DDR) pathways of homologous recombination repair and mismatch repair (HRR-MMR) or HRR and base excision repair (HRR-BER; defined as co-mut+) that are associated with increased TMB and neoantigen load and increased levels of immune gene expression signatures. In four public clinical cohorts, co-mut+ patients presented a higher objective response rate and a longer progression-free survival or overall survival than co-mut− patients. Overall, identification of DDR comutations in HRR-MMR or HRR-BER as predictors of response to ICB provides a potentially convenient approach for future clinical practice. Significance: Identification of comutations in specific DDR pathways as predictors of superior survival outcomes in response to immune checkpoint blockade provide a clinically convenient approach for estimation of tumor mutational burden and delivery of ICB therapy. Cancer Res; 78(22); 6486–96. ©2018 AACR.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81630071 and 81330062)
- National Key R&D Program of China (2016YFC0902300)
- National High Technology Research and Development (SS2015AA020403)
- CAMS (2016-I2M-3-008)
- China National Natural Sciences Foundation (81472206)
- China National Natural Sciences Foundation (81871889)
- Beijing Natural Science Foundation (7172045)
- Beijing Novel Program (Z141107001814051)
This publication has 34 references indexed in Scilit:
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the IndicationNew England Journal of Medicine, 2017
- Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV diseaseCancer Immunology, Immunotherapy, 2017
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.Journal of Clinical Oncology, 2015